Published in Antimicrob Agents Chemother on August 13, 2012
A call to action for antimicrobial stewardship in the emergency department: approaches and strategies. Ann Emerg Med (2012) 1.80
Clinical management of infections caused by multidrug-resistant Enterobacteriaceae. Ther Adv Infect Dis (2013) 0.88
Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia Coli. an exploratory case-control study. PLoS One (2013) 0.84
Meta-analysis of proportion estimates of Extended-Spectrum-Beta-Lactamase-producing Enterobacteriaceae in East Africa hospitals. Antimicrob Resist Infect Control (2016) 0.81
Intestinal decontamination of multidrug-resistant Klebsiella pneumoniae after recurrent infections in an immunocompromised host. Diagn Microbiol Infect Dis (2014) 0.78
Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst (1959) 94.48
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care (2005) 30.41
The impact of confounder selection criteria on effect estimation. Am J Epidemiol (1989) 13.34
Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother (2004) 10.64
Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection (1984) 7.53
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis (2001) 4.79
Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA (2003) 4.09
Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother (2004) 3.69
Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother (2007) 3.55
Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2006) 3.33
The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect (2008) 3.28
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med (2008) 3.23
Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol (2004) 3.20
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis (2002) 2.99
First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother (2007) 2.84
Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis (2010) 2.76
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control (2002) 2.49
Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother (2000) 2.27
Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA (1999) 2.16
CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from Enterobacteriaceae isolated in France. Antimicrob Agents Chemother (2002) 2.09
Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother (2009) 1.94
Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis (2004) 1.88
Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis (2002) 1.83
Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis (2001) 1.59
Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2005) 1.49
Development and clinical validation of a molecular diagnostic assay to detect CTX-M-type beta-lactamases in Enterobacteriaceae. Clin Microbiol Infect (2007) 1.36
Prevalence of CTX-M beta-lactamases in Philadelphia, Pennsylvania. J Clin Microbiol (2009) 1.27
A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organisms. Clin Infect Dis (2006) 1.26
Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis (2005) 1.22
Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis (2006) 1.22
Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect (2006) 1.16
Virulence factors in Escherichia coli with CTX-M-15 and other extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother (2007) 1.15
CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors. J Clin Microbiol (2006) 1.15
Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. Int J Antimicrob Agents (2006) 1.12
Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital. Clin Microbiol Infect (2011) 1.02
Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. J Hosp Infect (2006) 1.01
Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol (2009) 0.95
High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol (2005) 0.89
The categorization of prior antibiotic use: impact on the identification of risk factors for drug resistance in case control studies. Am J Infect Control (2007) 0.86
Risk factors and outcomes of Escherichia coli bacteremia caused by strains that produce CTX-M or non-CTX-M extended-spectrum-beta-lactamases. Eur J Clin Microbiol Infect Dis (2010) 0.86
Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance. Am J Infect Control (2010) 0.81
Clinico-epidemiological features of infections caused by CTX-M type extended spectrum beta lactamase-producing Escherichia coli in hospitalised patients. J Infect (2006) 0.80
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf (2007) 5.93
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis (2010) 5.34
Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med (2003) 5.09
Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis (2008) 3.56
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell (2011) 3.42
The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf (2005) 3.24
Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol (2009) 2.73
Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry (2003) 2.69
A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J Neurosci Methods (2009) 2.55
Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. Neuropsychology (2012) 2.54
Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA (2003) 2.51
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ (2002) 2.46
Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol (2002) 2.39
SHEA/APIC guideline: infection prevention and control in the long-term care facility, July 2008. Infect Control Hosp Epidemiol (2008) 2.35
Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. Infect Control Hosp Epidemiol (2010) 2.29
Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA (2006) 2.26
Antibiotics, acne, and Staphylococcus aureus colonization. Arch Dermatol (2011) 2.22
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother (2012) 2.17
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 2.16
Surveillance definitions of infections in long-term care facilities: revisiting the McGeer criteria. Infect Control Hosp Epidemiol (2012) 2.15
Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf (2002) 2.12
Differences in facial expressions of four universal emotions. Psychiatry Res (2004) 2.11
Why is long-term therapy required to cure tuberculosis? PLoS Med (2007) 2.03
Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy. Arch Intern Med (2003) 2.02
Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis (2006) 1.96
Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med (2009) 1.86
Surveillance cultures for detection of methicillin-resistant Staphylococcus aureus: diagnostic yield of anatomic sites and comparison of provider- and patient-collected samples. Infect Control Hosp Epidemiol (2009) 1.85
Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics (2011) 1.84
Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis (2004) 1.83
Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med (2005) 1.82
Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf (2010) 1.78
Quality of care indicators for gout management. Arthritis Rheum (2004) 1.77
Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol (2006) 1.76
Recommendations for metrics for multidrug-resistant organisms in healthcare settings: SHEA/HICPAC Position paper . Infect Control Hosp Epidemiol (2008) 1.73
Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance. Infect Control Hosp Epidemiol (2005) 1.71
Telling truth from lie in individual subjects with fast event-related fMRI. Hum Brain Mapp (2005) 1.70
Sex differences in temporo-limbic and frontal brain volumes of healthy adults. Cereb Cortex (2002) 1.69
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst (2012) 1.69
Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care (2007) 1.66
Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry (2007) 1.65
Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophr Bull (2006) 1.64
The preventability of ventilator-associated events. The CDC Prevention Epicenters Wake Up and Breathe Collaborative. Am J Respir Crit Care Med (2015) 1.64
Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf (2011) 1.63
Reemergence of gram-negative health care-associated bloodstream infections. Arch Intern Med (2006) 1.63
Long-term effects of culture of preimplantation mouse embryos on behavior. Proc Natl Acad Sci U S A (2004) 1.57
"Equal" contributions and credit: an emerging trend in the characterization of authorship. Ann Epidemiol (2010) 1.57
SHEA/APIC Guideline: Infection prevention and control in the long-term care facility. Am J Infect Control (2008) 1.56
Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One (2011) 1.54
Use of the internet to enhance infectious disease surveillance and outbreak investigation. Biosecur Bioterror (2006) 1.49
Child care center exclusion policies and directors' opinions on the use of antibiotics. Infect Control Hosp Epidemiol (2010) 1.48
Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med (2006) 1.47
Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J (2004) 1.45
Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship. Infect Control Hosp Epidemiol (2014) 1.45
Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a Combination Antibiogram. Infect Control Hosp Epidemiol (2006) 1.45
Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS (2002) 1.44
Represcription of penicillin after allergic-like events. J Allergy Clin Immunol (2004) 1.44
Evaluation of mannitol salt agar, CHROMagar Staph aureus and CHROMagar MRSA for detection of meticillin-resistant Staphylococcus aureus from nasal swab specimens. J Med Microbiol (2007) 1.44
Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry (2012) 1.42
Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect Control Hosp Epidemiol (2006) 1.42
Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis (2005) 1.39
Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf (2003) 1.38
Amphotericin B-induced nephrogenic diabetes insipidus in a case of cryptococcemia. Intern Med (2005) 1.38
Household transmission of meticillin-resistant Staphylococcus aureus and other staphylococci. Lancet Infect Dis (2012) 1.38
Automated laboratory reporting of infectious diseases in a climate of bioterrorism. Emerg Infect Dis (2003) 1.37
Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis (2005) 1.35
Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol (2010) 1.34
Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol (2009) 1.33
Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics (2005) 1.33
Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord (2005) 1.32
Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med (2002) 1.32
Fluoroquinolone-resistant Escherichia coli carriage in long-term care facility. Emerg Infect Dis (2005) 1.32
Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol (2010) 1.30
Neuropsychological deficits among patients with late-onset minor and major depression. Arch Clin Neuropsychol (2003) 1.30
Impact of freezing on the future utility of archived surveillance culture specimens. Infect Control Hosp Epidemiol (2007) 1.29
Prevalence of CTX-M beta-lactamases in Philadelphia, Pennsylvania. J Clin Microbiol (2009) 1.27
HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time. J Acquir Immune Defic Syndr (2007) 1.26
How long is the window of opportunity between adherence failure and virologic failure on efavirenz-based HAART? HIV Clin Trials (2008) 1.25
Visual attention circuitry in schizophrenia investigated with oddball event-related functional magnetic resonance imaging. Am J Psychiatry (2007) 1.24
A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. Clin Infect Dis (2005) 1.22
Brain region and sex differences in age association with brain volume: a quantitative MRI study of healthy young adults. Am J Geriatr Psychiatry (2002) 1.21
Impact of diversity of colonizing strains on strategies for sampling Escherichia coli from fecal specimens. J Clin Microbiol (2008) 1.19
Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry (2006) 1.18
A 65-kilobase pathogenicity island is unique to Philadelphia-1 strains of Legionella pneumophila. J Bacteriol (2003) 1.18